Thomas Reilly's most recent trade in Tvardi Therapeutics Inc. was a trade of 2,044 Common Stock done at an average price of $11.4 . Disclosure was reported to the exchange on March 3, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.38 per share. | 03 Mar 2022 | 2,044 | 37,811 (0%) | 0% | 11.4 | 23,261 | Common Stock |
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 20,000 | 34,522 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.29 per share. | 25 Feb 2022 | 5,333 | 39,855 (0%) | 0% | 10.3 | 54,877 | Common Stock |
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.20 per share. | 30 Aug 2021 | 1,982 | 3,352 (0%) | 0% | 14.2 | 28,144 | Common Stock |
| Tvardi Therapeutics Inc | Thomas Reilly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2021 | 5,334 | 5,334 (0%) | 0% | 0 | Common Stock |